Login to Your Account



Neurocrine, Sepracor Race To Unseat Ambien For Insomnia

By Randall Osborne


Monday, June 16, 2003
With a Phase III program in full swing for its insomnia drug Indiplon (formerly NBI-34060), Neurocrine Biosciences Inc. unveiled full Phase II data for the first time during the meeting of the Associated Professional Sleep Societies earlier this month in Chicago. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription